Ackman, in email, says supports Valeant CEO Pearson
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Valeant (VRX) Price Target Cut to $195 at Guggenheim; Thesis Intact
November 6, 2015 6:29 AM ESTGuggenheim analyst Louise Chen lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $195.00 (from $300.00) but maintained a Buy rating saying the investment thesis remains intact.
Chen commented, "We are lowering our PT for VRX to $195 from $300. The decrease in our PT is... More
Is a 'Fire Sale' in Store for Valeant Pharma (VRX)?
November 5, 2015 3:42 PM ESTWith all hope lost, speculators wonder if a fire sale may be the last resort to stop the bleeding in Valeant Pharma (NYSE: VRX) shares.
Trades are keenly focusing on the last line in Bill Ackman's letter supporting Valeant Pharma... More
Worst Case Valeant (VRX) is a Buy - Mizuho
November 5, 2015 3:13 PM ESTMizuho Securities analyst Irina Koffler said worse case analysis and Valeant Pharmaceuticals (NYSE: VRX) is a Buy. The firm reiterated a Buy rating and $155 price target.
The stock is no longer trading on fundamentals in our view. We look at a liquidation valuation in the extreme case that management is ousted and the business is put up for sale under distressed conditions. We conclude shares are undervalued and reiterate our BUY rating
Key points:
We try to remain rational and reiterate our BUY rating: We understand the... More